Angela Mingarelli joins TWiV to discuss whether the gut microbiota of bats confers tolerance to influenza virus infection in mice, and primate hemorrhagic fever-causing arteriviruses that can reproduce in human cells and might be capable of infecting humans.
In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland.
Kathryn Hanley joins TWiV to discuss her career and the research in her laboratory on the molecular biology, evolution and ecology of emerging RNA viruses and their insect vectors.
In his weekly clinical update Dr. Griffin discusses high points of the multi-national monkeypox outbreaks, monkeypox virus genome mutations, possible occupational infection of healthcare workers with monkeypox virus, rates of monkeypox cases by vaccination status, protection of SARS-CoV-2 infection against reinfection, Paxlovid significantly reduces COVID-19 hospitalizations and deaths, and rebound in COVID19 with and without Paxlovid treatment.
Paul Offit returns to TWiV for a discussion of SARS-CoV-2 bivalent boosters containing ancestral and Omicron spike mRNAs, including their composition, why they are being recommended by CDC, and who would benefit the most from them.
In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID.
